Heart failure & cardiomyopathiesCohort study
Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry)
- Retrospective multicentre registry study
- 9 tertiary care centres
Authors' conclusion
Although often a last resort, VT ablation in patients with LVAD is feasible and safe when performed in experienced centres. These patients suffer from a high scar burden, and cardiomyopathy-associated rather than cannula-related scar seems to be the dominant substrate. Ventricular tachycardia recurrence is high despite extensive treatment, and the overall prognosis is limited.
Study context
- Population
- Patients with LVAD referred for ventricular tachycardia (VT) ablation
- Participants
- 69 patients · 72 ablation procedures
Main finding
As reported in the abstract
VT mechanism, acute procedural result, VT recurrence and mortality after VT ablation · median follow-up 283 days (IQR 70-587 days)
- Scar-related re-entry VT
- 76/96 VTs; 79%
- LVAD cannula-related VT
- 19/96 VTs (20%)
- Non-inducibility of any VT
- 28/72 procedures (39%)
- Transplanted
- 10/69 (14%)
- Died
- 26/69 (38%)
- Free from VT
- 16/69 (23%)
- Lost to follow-up
- 3/69
Observational data: associations, not effects.
Safety
LVAD-related complications
- No LVAD-related complication observed
Original publication
Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry). Europace. Published 18 March 2025. doi:10.1093/europace/euaf054
Summarised from the published abstract; every number is checked against it